CCXI ChemoCentryx, Inc.

7.18
+0  (1%)
Previous Close 7.08
Open 7.12
Price To book 6.82
Market Cap 345.74M
Shares 48,153,000
Volume 63,906
Short Ratio 18.06
Av. Daily Volume 120,432

SEC filingsSee all SEC filings

  1. DEF 14A - Other definitive proxy statements 17752837
  2. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17688568
  3. 8-K - Current report 17688446
  4. 8-K - Current report 17659292
  5. 8-K - Current report 17608663

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Partner required to continue with Phase 3 program
Vercirnon CCX282
Crohn's disease
Phase 2 top-line data released Dec 12 2014. Partner required for further development.
CCX140
Diabetic nephropathy
Phase 1b early response data released September 1, 2016. Initial PFS data released January 20, 2017.
CCX872
Non-resectable pancreatic cancer
Phase 2 data presented at ASN Kidney Week - November 17, 2016.
CCX168
Atypical Hemolytic Uremic Syndrome (aHUS)
Phase 3 initiated December 2016.
CCX168 (ADVOCATE)
Associated vasculitis (AAV)